Comparison between venous infliximab blood level and bloodspot-technology in children with inflammatory bowel disease.

Comparison between venous infliximab blood level and bloodspot-technology in children with inflammatory bowel disease. - Comparison between venous infliximab blood level and bloodspot-technology.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45579

Enrollment

Registered

2018-03-06

Start date

2017-10-20

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic inflammation of the bowel Inflammatory bowel disease

Interventions

Bloodspot technology

Inflammatory Bowel Disease

Infliximablevel

Pediatric

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: - Patients with Crohn's disease, Ulcerative Colitis and IBD-unclassified - Age from six to sixteen years old - Treatment with infliximab - Indication to determine infliximablevel and anti-drug-antibodies - Obtain informed consent

Exclusion criteria

Exclusion criteria: - Age under six and above seventeen years old - No informed consent - Children and parents/guardians who do not speak the Dutch language

Design outcomes

Primary

Measure	Time frame
The primary study objective is comparison between the venous infliximab blood level/anti-drug-antibodies and the bloodspot-technology.	—

Secondary

Measure	Time frame
Not apply	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)